Bridget Reilly Durkin, MD

Tyler G. Boyce, Ashish P. Thakrar, MD, MS, Bridget R. Durkin, MD, MBE, Emily R. Casey, PharmD, BCPMP, Lin Xu, MS, Margaret Lowenstein, MD, MPhil, MSHP "Trends in Hospital and Intensive Care Unit Admissions for Medetomidine Withdrawal" , in review: 2026

Ann A. Soliman, MD, Jennifer M. Olenik, MD, Alana Sagin, MD, MSEd, Bridget Durkin, MD, MBE Qualitative Study of Preclinical Medical Student Reflections on Required Palliative Care Experience , Journal of Pain and Symptom Management, 70(3): 2025,287-294

Samantha Huo, MD; Kory London, MD; Lauren Murphy, MD; Emily Casey, PharmD; Philip Durney, MD; Maya Arora; Rita McKeever, MD; Abriana Tasillo, MD; Dennis Goodstein, PharmD; Brendan Hart, MD, PhD; Jeanmarie Perrone, MD "Notes from the Field: Suspected Medetomidine Withdrawal Syndrome Among Fentanyl-Exposed Patients — Philadelphia, Pennsylvania, September 2024–January 2025" , Morbidity and Mortality Weekly Report: 2025,266-268

Bridget Durkin “Managing the Clinical and Ethical Challenges of Naloxone in Hospitalized Palliative Care Patients.” , Annual Assembly of Hospice & Palliative Care. Poster Presentation. Montreal, Canada: 2023

Maley JH, et al “Six-Month Impairment in Cognition, Mental Health, and Physical Function Following COVID-19-Associated Respiratory Failure.” , Critical Care Exploration, 4(4): 2022